公开(公告)号：US20250059207A1

公开(公告)日：2025-02-20

申请号：US18718735

申请日：2022-12-27

Applicant: 858 Therapeutics, Inc.

Inventor： Zacharia S. CHERUVALLATH ,  James M. VEAL ,  Jeffrey A. STAFFORD ,  Christopher MCBRIDE

IPC: C07D519/00 ,  A61K31/4375 ,  A61K31/438 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/4995 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/538 ,  A61K31/5386 ,  A61P35/02 ,  C07D471/04

Abstract: The present disclosure relates to 6,6-fused heterocyclic compounds and related compounds and their use in treating a disease or condition responsive to modulation or inhibition of METTL3.

公开(公告)号：US20250057829A1

公开(公告)日：2025-02-20

申请号：US18806773

申请日：2024-08-16

Applicant: Boehringer Ingelheim International GmbH

Inventor： Roberto Matias NORDABY ,  Nima SOLEYMANLOU

IPC: A61K31/4545 ,  A61K31/496 ,  A61K31/499 ,  A61K31/4995 ,  A61K31/501 ,  A61K31/5386

Abstract: Disclosed are methods for treating focal segmental glomerulosclerosis (FSGS), comprising administering to a patient in need thereof a pharmaceutically effective amount of a compound of formula (I), wherein R1 to R7, A, L and Y are as defined herein. Also disclosed are pharmaceutical compositions comprising the compound of formula (I) and their use for treating FSGS.

公开(公告)号：US20250051344A1

公开(公告)日：2025-02-13

申请号：US18737832

申请日：2024-06-07

Applicant: Nurix Therapeutics, Inc.

Inventor： Katherine Keenan ,  Rishab N. Iyer ,  Tim R. Kane ,  Jake C. Swartzel

IPC: C07D487/10 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5386 ,  A61K31/551 ,  C07D401/14 ,  C07D413/14 ,  C07D471/04 ,  C07D471/08 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08 ,  C07D491/107 ,  C07D498/04 ,  C07D498/10 ,  C07D519/00

Abstract: The present disclosure provides bifunctional compounds as selective SMARCA2 degraders via ubiquitin proteosome pathway, and their therapeutic use for treating cancers.

公开(公告)号：US20250009653A1

公开(公告)日：2025-01-09

申请号：US18689579

申请日：2022-09-08

Applicant: KINDEVA DRUG DELIVERY L.P.

Inventor： Philip COCKS ,  Sarah WRIGGLESWORTH ,  Connor MCCORMACK ,  James LISTER ,  Lauren HARRISON ,  Chad HARALDSON ,  Joseph MILLER ,  James DRAKE ,  Stephen STEIN

IPC: A61K9/00 ,  A61K9/08 ,  A61K31/40 ,  A61K31/439 ,  A61K31/5386 ,  A61K47/06 ,  A61K47/10

Abstract: A composition comprising a solution comprising an active pharmaceutical ingredient comprising an anticholinergic agent, such as ipratropium bromide, and a propellant comprising HFA-152a, HFO-1234ze(E), or both. A metered dose inhaler comprising a metering valve a canister; and an actuator comprising an actuator nozzle; wherein the canister comprises said composition.

公开(公告)号：US20250002471A1

公开(公告)日：2025-01-02

申请号：US18268469

申请日：2021-12-21

Applicant: Gilead Sciences, Inc.

Inventor： Stephen E. Ammann ,  Eda Y. Canales ,  Weng K. Chang ,  Scott E. Lazerwith ,  Daniel G. Shore

IPC: C07D401/14 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/497 ,  A61K31/4985 ,  A61K31/499 ,  A61K31/4995 ,  A61K31/506 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/55 ,  A61K31/551 ,  C07D401/04 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08 ,  C07D487/10 ,  C07D495/04 ,  C07D498/10

Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.

公开(公告)号：US20240423977A1

公开(公告)日：2024-12-26

申请号：US18651214

申请日：2024-04-30

Applicant: HANGZHOU POLYMED BIOPHARMACEUTICALS, INC.

Inventor： Jason Shaoyun XIANG ,  Lei WU ,  Bing ZHANG ,  Qiang ZHANG ,  Gang YANG ,  Rui XU ,  Shuai YANG ,  Yue WU ,  Suyue WANG ,  Rui YANG

IPC: A61K31/496 ,  A61K31/4545 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/5386 ,  C07D401/14 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04 ,  C07D498/08 ,  C07D519/00

Abstract: Disclosed in the present invention are a five-membered ring-fused six-membered ring compound, a preparation method therefor, and a pharmaceutical composition and the use thereof. Provided in the present invention is a compound as represented by formula (I), or a pharmaceutically acceptable salt or an isotope compound thereof. The compound of the present invention has an inhibition and/or degradation effect on IRAK4.

公开(公告)号：US12171768B2

公开(公告)日：2024-12-24

申请号：US17651201

申请日：2022-02-15

Applicant: Kymera Therapeutics, Inc.

Inventor： Jared Gollob ,  Jeffrey Davis ,  Alice Mcdonald ,  Haojing Rong

IPC: A61K31/5386 ,  A61K9/00 ,  A61K9/20 ,  A61K9/28 ,  A61P31/00

Abstract: The present invention provides IRAK4 degraders, formulations and unit dosage forms thereof, and methods of use thereof.

公开(公告)号：US20240400560A1

公开(公告)日：2024-12-05

申请号：US18692022

申请日：2022-09-15

Applicant: Shionogi & Co., Ltd. ,  NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY

Inventor： Yoshiyuki TAODA ,  Shota UEHARA ,  Yuseke SAKO ,  Keiichiro HIRAI

IPC: C07D471/04 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5386 ,  A61P31/14 ,  C07D401/06 ,  C07D403/06 ,  C07D487/08 ,  C07D491/048 ,  C07D519/00

Abstract: The present invention provides a compound exhibiting coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same.
Provided is a compound represented by Formula (I): wherein carbon atom a and carbon atom b are each a carbon atom constituting ring A, the ring A is substituted aromatic carbocycle or the like, R1 is substituted or unsubstituted aromatic heterocyclyl or the like, R2 is substituted or unsubstituted 6-membered aromatic carbocyclyl or the like, m is 1 or the like, R5as are each independently a hydrogen atom or the like, R5bs are each independently a hydrogen atom or the like, n is 1 or the like, R4a is a hydrogen atom or the like, and R4a is a hydrogen atom or the like. Alternatively, provided is a pharmaceutically acceptable salt of the compound.

公开(公告)号：US20240383917A1

公开(公告)日：2024-11-21

申请号：US18684549

申请日：2022-08-18

Applicant: Xizang Haisco Pharmaceutical Co., Ltd.

Inventor： Chen ZHANG ,  Yuting LIAO ,  Guozhi ZHU ,  Dachao TANG ,  Yan YU ,  Pingming TANG ,  Xinfan CHENG ,  Yao LI ,  Jia NI ,  Pangke YAN

IPC: C07D498/10 ,  A61K31/407 ,  A61K31/438 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/5386 ,  C07D401/06 ,  C07D401/14 ,  C07D403/06 ,  C07D405/14 ,  C07D471/10 ,  C07D491/08 ,  C07D491/107 ,  C07D495/10

Abstract: Provided are a compound as shown in general formula (I), or a stereoisomer, deuterate, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal thereof, an intermediate thereof, a preparation method therefor, and the use thereof in the preparation of a drug for treating a disease associated with the activity or expression quantity of complement factor B.

公开(公告)号：US20240376118A1

公开(公告)日：2024-11-14

申请号：US18691878

申请日：2022-09-13

Applicant: MONTELINO THERAPEUTICS, INC.

Inventor： Jenny DESANTIS ,  Roy Joseph VAZ ,  Michela ELEUTERI

IPC: C07D491/08 ,  A61K31/5377 ,  A61K31/5386 ,  C07D417/14

Abstract: The present invention relates to bi-functional compounds which function to recruit endogenous proteins to an E3 ubiquitin ligase for degradation, and methods for using same. More specifically, the present disclosure provides specific proteolysis targeting chimera (PROTAC) molecules which find utility as modulators of targeted ubiquitination of a variety of polypeptides and other proteins, in particular the androgen receptor of a slice variant of AR which lacks the LBD, labelled as AR-V7, which are then degraded and/or otherwise inhibited by the compounds as described herein.